Engility®CTMS Selected by Leading US Health Outcomes and Technology Company for its Clinical Trial Programmes
PHARMASEAL, a new provider of clinical trial management and governance solutions, announced today that a leading US health outcomes and technology company has selected Engility® Clinical Trial Management system for the management and oversight of its clinical trial programmes.
In the field of health outcomes and technology, companies are looking to leverage big clinical data and artificial intelligence (AI) to better understand, compare, and predict patient outcomes. The task of combining real-world evidence (RWE), clinical registries and AI technologies can be challenging. Engility® was chosen to provide a validated system for managing clinical trial information, reduce data duplication and improve trial collaboration.
Engility CTMS is a modern cloud-based enterprise trial management system used by medical device, biopharmaceutical and CRO’s to improve how they manage and control clinical trials. With support for multiple sourcing models, flexible trial designs including centralised/virtual/remote trials, Engility CTMS is ideally placed to support good clinical practice (GCP E6) requirements and spearhead clinical operational process improvements.
Daljit Cheema, Founder and CEO of PHARMASEAL commented, “We are delighted that our integrated enterprise platform, Engility, has been selected and licensed to help drive new insights for this company. Our innovative platform utilises advanced engineering offering enterprise management with rapid deployment, an intuitive user interface and interoperability with other eClinical applications to optimise governance and oversight. At PHARMASEAL, we have the vision to create smarter technologies for the improvement of human health and we are excited to see what possibilities emerge from this collaboration for transforming the future of healthcare.”
To learn more about PHARMASEAL’s solutions, please visit www.pharmaseal.co or email firstname.lastname@example.org
For all press enquiries please contact Sally Vernon via email email@example.com